These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31648992)

  • 21. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
    Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin D enhances responses to interferon-β in MS.
    Feng X; Wang Z; Howlett-Prieto Q; Einhorn N; Causevic S; Reder AT
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):e622. PubMed ID: 31582399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy.
    Karam RA; Rezk NA; Amer MM; Fathy HA
    IUBMB Life; 2016 Sep; 68(9):727-34. PubMed ID: 27346865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta.
    Ozenci V; Kouwenhoven M; Teleshova N; Pashenkov M; Fredrikson S; Link H
    J Neuroimmunol; 2000 Aug; 108(1-2):236-43. PubMed ID: 10900359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
    Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linc-MAF-4 regulates Th1/Th2 differentiation and is associated with the pathogenesis of multiple sclerosis by targeting MAF.
    Zhang F; Liu G; Wei C; Gao C; Hao J
    FASEB J; 2017 Feb; 31(2):519-525. PubMed ID: 27756768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis.
    Cosentino M; Zaffaroni M; Ferrari M; Marino F; Bombelli R; Rasini E; Frigo G; Ghezzi A; Comi G; Lecchini S
    J Neuroimmunol; 2005 May; 162(1-2):112-21. PubMed ID: 15833366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosis.
    Haghikia A; Faissner S; Pappas D; Pula B; Akkad DA; Arning L; Ruhrmann S; Duscha A; Gold R; Baranzini SE; Malhotra S; Montalban X; Comabella M; Chan A
    Mult Scler; 2015 Sep; 21(10):1262-70. PubMed ID: 25480861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis.
    Tao Y; Zhang X; Chopra M; Kim MJ; Buch KR; Kong D; Jin J; Tang Y; Zhu H; Jewells V; Markovic-Plese S
    J Immunol; 2014 Jun; 192(12):5610-7. PubMed ID: 24850724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.
    Genç K; Dona DL; Reder AT
    J Clin Invest; 1997 Jun; 99(11):2664-71. PubMed ID: 9169496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amelioration of Experimental Autoimmune Encephalomyelitis in Mice by Interferon-Beta Gene Therapy, Using a Long-Term Expression Plasmid Vector.
    Hamana A; Takahashi Y; Tanioka A; Nishikawa M; Takakura Y
    Mol Pharm; 2017 Apr; 14(4):1212-1217. PubMed ID: 28257578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance.
    Hundeshagen A; Hecker M; Paap BK; Angerstein C; Kandulski O; Fatum C; Hartmann C; Koczan D; Thiesen HJ; Zettl UK
    J Neuroinflammation; 2012 Jun; 9():140. PubMed ID: 22727118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon inhibitory activity in patients with multiple sclerosis.
    Chadha K; Weinstock-Guttman B; Zivadinov R; Bhasi K; Muhitch J; Feichter J; Tamaño-Blanco M; Abdelrahman N; Ambrus J; Munschauer F; Ramanathan M
    Arch Neurol; 2006 Nov; 63(11):1579-84. PubMed ID: 17101826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
    Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V
    Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.
    Malhotra S; Río J; Urcelay E; Nurtdinov R; Bustamante MF; Fernández O; Oliver B; Zettl U; Brassat D; Killestein J; Lechner-Scott J; Drulovic J; Chan A; Martinelli-Boneschi F; García-Merino A; Montalban X; Comabella M
    Brain; 2015 Mar; 138(Pt 3):644-52. PubMed ID: 25586466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon Signature's Members, a Novel Altered Correlation upon Interferon-β Treatment in Multiple Sclerosis Patients.
    Jabbari S; Hosseinpourfeizi M; Safaralizadeh R; Baradaran B
    Curr Mol Med; 2024; 24(10):1301-1306. PubMed ID: 37842895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.